The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2 - International RET mutation consortium analysis

被引:852
作者
Eng, C
Clayton, D
Schuffenecker, I
Lenoir, G
Cote, G
Gagel, RF
vanAmstel, HKP
Lips, CJM
Nishisho, I
Takai, SI
Marsh, DJ
Robinson, BG
FrankRaue, K
Raue, F
Xue, FY
Noll, WW
Romei, C
Pacini, F
Fink, M
Niederle, B
Zedenius, J
Nordenskjold, M
Komminoth, P
Hendy, GN
Gharib, H
Thibodeau, SN
Lacroix, A
Frilling, A
Ponder, BAJ
Mulligan, LM
机构
[1] QUEENS UNIV,DEPT PAEDIAT,KINGSTON,ON K7L 3N6,CANADA
[2] UNIV CAMBRIDGE,CANC RES CAMPAIGN,HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 1TN,ENGLAND
[3] UNIV CAMBRIDGE,INST PUBL HLTH,MRC,BIOSTAT UNIT,CAMBRIDGE CB2 1TN,ENGLAND
[4] INT AGCY RES CANC,F-69372 LYON,FRANCE
[5] UNIV TEXAS,MD ANDERSON CANC CTR,HOUSTON,TX
[6] UNIV UTRECHT,DEPT INTERNAL MED,UTRECHT,NETHERLANDS
[7] UNIV UTRECHT,CLIN GENET CTR,UTRECHT,NETHERLANDS
[8] OSAKA UNIV,SCH MED,DEPT MED GENET,OSAKA,JAPAN
[9] UNIV SYDNEY,ROYAL N SHORE HOSP,KOLLING INST MED RES,MOL GENET UNIT,ST LEONARDS,NSW 2065,AUSTRALIA
[10] UNIV HEIDELBERG,DEPT INTERNAL MED 1,HEIDELBERG,GERMANY
[11] DARTMOUTH HITCHCOCK MED CTR,DEPT PATHOL,LEBANON,NH 03766
[12] UNIV PISA,INST ENDOCRINOL,PISA,ITALY
[13] UNIV VIENNA,DEPT SURG,A-1010 VIENNA,AUSTRIA
[14] KAROLINSKA HOSP,DEPT MOL MED,S-10401 STOCKHOLM,SWEDEN
[15] KAROLINSKA HOSP,DEPT SURG,S-10401 STOCKHOLM,SWEDEN
[16] KAROLINSKA HOSP,DEPT CLIN GENET,S-10401 STOCKHOLM,SWEDEN
[17] UNIV ZURICH,DEPT PATHOL,CH-8006 ZURICH,SWITZERLAND
[18] ROYAL VICTORIA HOSP,CALCIUM RES LAB,MONTREAL,PQ H3A 1A1,CANADA
[19] MAYO CLIN,DIV ENDOCRINOL,ROCHESTER,MN
[20] HOP HOTEL DIEU,CTR RECH,MONTREAL,PQ,CANADA
[21] UNIV HAMBURG,DEPT SURG,HAMBURG,GERMANY
[22] QUEENS UNIV,DEPT PATHOL,KINGSTON,ON K7L 3N6,CANADA
[23] QUEENS UNIV,DEPT PAEDIAT,KINGSTON,ON,CANADA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1996年 / 276卷 / 19期
关键词
D O I
10.1001/jama.276.19.1575
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective.-Multiple endocrine neoplasia type 2 (MEN 2) is an autosomal dominant disorder. The 3 recognized subtypes include MEN 2A, characterized by medullary thyroid carcinoma (MTC), pheochromocytoma (pheo), and hyperparathyroidism (HPT); MEN 2B, by MTC, pheo, and characteristic stigmata; and familial MTC (FMTC), by the presence of MTC only. The purpose of this study was to establish the relationship between specific mutations and the presence of certain disease features in MEN 2 which could help in clinical decision making. Design.-Correlative survey study of 477 MEN 2 families. Setting.-Eighteen tertiary referral centers worldwide. Patients.-A total of 477 independent MEN 2 families. Main Outcome Measures.-Association between the position and type of germline mutation in the RET proto-oncogene and the presence or absence of MTC, pheo, HPT, and/or other features in a family. Results.-There is a statistically significant association between the presence of any mutation at a specific position (codon 634) and the presence of pheo and HPT. The presence of a specific mutation, CGC at codon 634, has yet to be associated with FMTC, Conversely, mutations at codons 768 and 804 are thus far seen only with FMTC, while codon 918 mutation is MEN 2B-specific. Rare families with both MEN 2 and Hirschsprung disease were found to have MEN 2-specific codon mutations. Patients with Hirschsprung disease presenting with such mutations should be monitored for the possible development of MEN 2 tumors. Conclusions.-This consortium analysis suggests that genotype-phenotype correlations do exist and, if made reliably absolute, could prove useful in the future in clinical management with respect to screening, surveillance, and prophylaxis, as well as provide insight into the genetic effects of particular mutations.
引用
收藏
页码:1575 / 1579
页数:5
相关论文
共 35 条
  • [1] MUTATION ANALYSIS OF THE RET RECEPTOR TYROSINE KINASE IN HIRSCHSPRUNG DISEASE
    ANGRIST, M
    BOLK, S
    THIEL, B
    PUFFENBERGER, EG
    HOFSTRA, RM
    BUYS, CHCM
    CASS, DT
    CHAKRAVARTI, A
    [J]. HUMAN MOLECULAR GENETICS, 1995, 4 (05) : 821 - 830
  • [2] DIVERSITY OF RET PROTOONCOGENE MUTATIONS IN FAMILIAL AND SPORADIC HIRSCHSPRUNG DISEASE
    ATTIE, T
    PELET, A
    EDERY, P
    ENG, C
    MULLIGAN, LM
    AMIEL, J
    BOUTRAND, L
    BELDJORD, C
    NIHOULFEKETE, C
    MUNNICH, A
    PONDER, BAJ
    LYONNET, S
    [J]. HUMAN MOLECULAR GENETICS, 1995, 4 (08) : 1381 - 1386
  • [3] BOLINO A, 1995, ONCOGENE, V10, P2415
  • [4] MUTATIONAL ANALYSIS OF MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A ASSOCIATED WITH HIRSCHSPRUNGS-DISEASE
    BORST, MJ
    VANCAMP, JM
    PEACOCK, ML
    DECKER, RA
    [J]. SURGERY, 1995, 117 (04) : 386 - 391
  • [5] SINGLE MISSENSE MUTATION IN THE TYROSINE KINASE CATALYTIC DOMAIN OF THE RET PROTOONCOGENE IS ASSOCIATED WITH MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B
    CARLSON, KM
    DOU, SS
    CHI, D
    SCAVARDA, N
    TOSHIMA, K
    JACKSON, CE
    WELLS, SA
    GOODFELLOW, PJ
    DONISKELLER, H
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (04) : 1579 - 1583
  • [6] MUTATIONS IN THE RET PROTOONCOGENE ARE ASSOCIATED WITH MEN 2A AND FMTC
    DONISKELLER, H
    DOU, SS
    CHI, D
    CARLSON, KM
    TOSHIMA, K
    LAIRMORE, TC
    HOWE, JR
    MOLEY, JF
    GOODFELLOW, P
    WELLS, SA
    [J]. HUMAN MOLECULAR GENETICS, 1993, 2 (07) : 851 - 856
  • [7] LOW-FREQUENCY OF GERMLINE MUTATIONS IN THE RET PROTOONCOGENE IN PATIENTS WITH APPARENTLY SPORADIC MEDULLARY-THYROID CARCINOMA
    ENG, C
    MULLIGAN, LM
    SMITH, DP
    HEALEY, CS
    FRILLING, A
    RAUE, F
    NEUMANN, HPH
    PONDER, MA
    PONDER, BAJ
    [J]. CLINICAL ENDOCRINOLOGY, 1995, 43 (01) : 123 - 127
  • [8] POINT MUTATION WITHIN THE TYROSINE KINASE DOMAIN OF THE RET PROTOONCOGENE IN MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B AND RELATED SPORADIC TUMORS
    ENG, C
    SMITH, DP
    MULLIGAN, LM
    NAGAI, MA
    HEALEY, CS
    PONDER, MA
    GARDNER, E
    SCHEUMANN, GFW
    JACKSON, CE
    TUNNACLIFFE, A
    PONDER, BAJ
    [J]. HUMAN MOLECULAR GENETICS, 1994, 3 (02) : 237 - 241
  • [9] ENG C, 1995, ONCOGENE, V10, P509
  • [10] ENG C, IN PRESS HUM MUTAT